{
  "nodes": [
    {
      "id": "node_001",
      "content": "Progression on erlotinib (± ramucirumab or bevacizumab), afatinib, gefitinib, dacomitinib",
      "parent_ids": [],
      "children_ids": [
        "node_002"
      ],
      "tree_ids": [],
      "footnote_labels": [
        "yy",
        "fff"
      ]
    },
    {
      "id": "node_002",
      "content": "T790M testing (category 1)",
      "parent_ids": [
        "node_001"
      ],
      "children_ids": [
        "node_003",
        "node_007"
      ],
      "tree_ids": [],
      "footnote_labels": []
    },
    {
      "id": "node_003",
      "content": "Asymptomatic",
      "parent_ids": [
        "node_002"
      ],
      "children_ids": [
        "node_004",
        "node_005",
        "node_006"
      ],
      "tree_ids": [],
      "footnote_labels": []
    },
    {
      "id": "node_004",
      "content": "Consider definitive local therapy (eg, SABR or surgery) for limited lesions",
      "parent_ids": [
        "node_003"
      ],
      "children_ids": [],
      "tree_ids": [],
      "footnote_labels": [
        "o",
        "zz"
      ]
    },
    {
      "id": "node_005",
      "content": "Osimertinib (if T790M+) (category 1)",
      "parent_ids": [
        "node_003"
      ],
      "children_ids": [
        "node_023"
      ],
      "tree_ids": [],
      "footnote_labels": [
        "ss"
      ]
    },
    {
      "id": "node_006",
      "content": "Continue afatinib or dacomitinib or gefitinib or erlotinib (± bevacizumab or ramucirumab) (if T790M-)",
      "parent_ids": [
        "node_003"
      ],
      "children_ids": [
        "node_024"
      ],
      "tree_ids": [],
      "footnote_labels": [
        "uu"
      ]
    },
    {
      "id": "node_007",
      "content": "Symptomatic",
      "parent_ids": [
        "node_002"
      ],
      "children_ids": [
        "node_008",
        "node_013"
      ],
      "tree_ids": [],
      "footnote_labels": []
    },
    {
      "id": "node_008",
      "content": "Brain",
      "parent_ids": [
        "node_007"
      ],
      "children_ids": [
        "node_009",
        "node_010",
        "node_011",
        "node_012"
      ],
      "tree_ids": [],
      "footnote_labels": [
        "ggg"
      ]
    },
    {
      "id": "node_009",
      "content": "Consider definitive local therapy (eg, SRS)",
      "parent_ids": [
        "node_008"
      ],
      "children_ids": [],
      "tree_ids": [],
      "footnote_labels": [
        "bbb"
      ]
    },
    {
      "id": "node_010",
      "content": "Osimertinib (if T790M+) (category 1)",
      "parent_ids": [
        "node_008"
      ],
      "children_ids": [
        "node_023"
      ],
      "tree_ids": [],
      "footnote_labels": [
        "ss"
      ]
    },
    {
      "id": "node_011",
      "content": "Continue afatinib or dacomitinib or gefitinib or erlotinib (± bevacizumab or ramucirumab) (if T790M-)",
      "parent_ids": [
        "node_008"
      ],
      "children_ids": [
        "node_024"
      ],
      "tree_ids": [],
      "footnote_labels": [
        "hhh",
        "uu"
      ]
    },
    {
      "id": "node_012",
      "content": "NCCN Guidelines for CNS Cancers",
      "parent_ids": [
        "node_008"
      ],
      "children_ids": [],
      "tree_ids": [
        "NCCN Guidelines for CNS Cancers"
      ],
      "footnote_labels": []
    },
    {
      "id": "node_013",
      "content": "Systemic",
      "parent_ids": [
        "node_007"
      ],
      "children_ids": [
        "node_014",
        "node_017"
      ],
      "tree_ids": [],
      "footnote_labels": []
    },
    {
      "id": "node_014",
      "content": "Limited progression",
      "parent_ids": [
        "node_013"
      ],
      "children_ids": [
        "node_015",
        "node_016"
      ],
      "tree_ids": [],
      "footnote_labels": [
        "zz"
      ]
    },
    {
      "id": "node_015",
      "content": "Consider definitive local therapy (eg, SABR or surgery)",
      "parent_ids": [
        "node_014"
      ],
      "children_ids": [
        "node_024"
      ],
      "tree_ids": [],
      "footnote_labels": [
        "o"
      ]
    },
    {
      "id": "node_016",
      "content": "Continue afatinib or dacomitinib or gefitinib or erlotinib (± bevacizumab or ramucirumab) (if T790M-)",
      "parent_ids": [
        "node_014"
      ],
      "children_ids": [
        "node_024"
      ],
      "tree_ids": [],
      "footnote_labels": [
        "uu"
      ]
    },
    {
      "id": "node_017",
      "content": "Multiple lesions",
      "parent_ids": [
        "node_013"
      ],
      "children_ids": [
        "node_018"
      ],
      "tree_ids": [],
      "footnote_labels": [
        "aaa",
        "ggg"
      ]
    },
    {
      "id": "node_018",
      "content": "Therapy for multiple lesions, below",
      "parent_ids": [
        "node_017"
      ],
      "children_ids": [
        "node_019",
        "node_021"
      ],
      "tree_ids": [],
      "footnote_labels": []
    },
    {
      "id": "node_019",
      "content": "T790M+",
      "parent_ids": [
        "node_018"
      ],
      "children_ids": [
        "node_020"
      ],
      "tree_ids": [],
      "footnote_labels": []
    },
    {
      "id": "node_020",
      "content": "Osimertinib (category 1) (if not previously given)",
      "parent_ids": [
        "node_019"
      ],
      "children_ids": [
        "node_023"
      ],
      "tree_ids": [],
      "footnote_labels": [
        "ss"
      ]
    },
    {
      "id": "node_021",
      "content": "T790M-",
      "parent_ids": [
        "node_018"
      ],
      "children_ids": [
        "node_022"
      ],
      "tree_ids": [],
      "footnote_labels": []
    },
    {
      "id": "node_022",
      "content": "Systemic therapy Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)",
      "parent_ids": [
        "node_021"
      ],
      "children_ids": [],
      "tree_ids": [
        "NSCL-K 1 of 5",
        "NSCL-K 2 of 5"
      ],
      "footnote_labels": [
        "ddd",
        "eee"
      ]
    },
    {
      "id": "node_023",
      "content": "Progression",
      "parent_ids": [
        "node_005",
        "node_010",
        "node_020"
      ],
      "children_ids": [],
      "tree_ids": [
        "NSCL-22"
      ],
      "footnote_labels": []
    },
    {
      "id": "node_024",
      "content": "Progression, see therapy for multiple lesions, below",
      "parent_ids": [
        "node_006",
        "node_011",
        "node_015",
        "node_016"
      ],
      "children_ids": [],
      "tree_ids": [],
      "footnote_labels": []
    }
  ],
  "tree_references": [
    {
      "from_tree": "NSCL-23",
      "to_tree": "NSCL-22",
      "description": "Next step upon progression after Osimertinib"
    },
    {
      "from_tree": "NSCL-23",
      "to_tree": "NCCN Guidelines for CNS Cancers",
      "description": "Guideline reference for CNS cancer treatment"
    },
    {
      "from_tree": "NSCL-23",
      "to_tree": "NSCL-K 1 of 5",
      "description": "Systemic therapy options for Adenocarcinoma"
    },
    {
      "from_tree": "NSCL-23",
      "to_tree": "NSCL-K 2 of 5",
      "description": "Systemic therapy options for Squamous Cell Carcinoma"
    },
    {
      "from_tree": "NSCL-23",
      "to_tree": "NSCL-D",
      "description": "Principles of Image-Guided Thermal Ablation Therapy"
    },
    {
      "from_tree": "NSCL-23",
      "to_tree": "NSCL-H",
      "description": "Principles of Molecular and Biomarker Analysis"
    },
    {
      "from_tree": "NSCL-23",
      "to_tree": "NSCL-J",
      "description": "Molecular or Biomarker-Directed Therapy for Advanced or Metastatic Disease"
    }
  ],
  "footnotes": [
    {
      "label": "o",
      "content": "IGTA therapy (eg, cryotherapy, microwave, radiofrequency) may be an option for select patients. See Principles of Image-Guided Thermal Ablation Therapy (NSCL-D)."
    },
    {
      "label": "nn",
      "content": "Principles of Molecular and Biomarker Analysis (NSCL-H)."
    },
    {
      "label": "rr",
      "content": "Molecular or Biomarker-Directed Therapy for Advanced or Metastatic Disease (NSCL-J)."
    },
    {
      "label": "ss",
      "content": "For PS 0–4."
    },
    {
      "label": "uu",
      "content": "Criteria for treatment with bevacizumab: nonsquamous NSCLC, and no recent history of hemoptysis."
    },
    {
      "label": "yy",
      "content": "Beware of flare phenomenon in subset of patients who discontinue TKI. If disease flare occurs, restart TKI."
    },
    {
      "label": "zz",
      "content": "Clinical trials have included up to 3 to 5 progressing sites."
    },
    {
      "label": "aaa",
      "content": "Consider a biopsy at time of progression to rule out SCLC transformation (approximately 6%) and biopsy or plasma testing to evaluate mechanisms of resistance. See Principles of Molecular and Biomarker Analysis (NSCL-H) and NCCN Guidelines for Small Cell Lung Cancer."
    },
    {
      "label": "bbb",
      "content": "Definitive local therapy of CNS disease can include asymptomatic lesions at risk for symptomatic progression based on factors including site, location, and edema."
    },
    {
      "label": "ddd",
      "content": "Afatinib + cetuximab may be considered in patients with disease progression on EGFR TKI therapy."
    },
    {
      "label": "eee",
      "content": "The data in the second-line setting suggest that PD-1/PD-L1 inhibitor monotherapy is less effective, irrespective of PD-L1 expression, in EGFR exon 19 deletion or exon 21 L858R, ALK+ NSCLC."
    },
    {
      "label": "fff",
      "content": "Plasma or tissue-based testing via broad molecular profiling should be considered at progression, for the T790M mutation and other genomic resistance mechanisms. If plasma-based testing is negative, tissue-based testing with rebiopsy material is strongly recommended. Practitioners may want to consider scheduling the biopsy concurrently with plasma testing referral."
    },
    {
      "label": "ggg",
      "content": "Consider osimertinib (regardless of T790M status) for progressive CNS disease or leptomeningeal disease. In the BLOOM study, osimertinib was used at 160 mg once daily for patients with leptomeningeal disease."
    },
    {
      "label": "hhh",
      "content": "In the randomized phase III trial of dacomitinib, patients with brain metastases were not eligible for enrollment. In the setting of brain metastases, consider other options."
    }
  ],
  "extraction_confidence": 0.95,
  "image_title": "EGFR EXON 19 DELETION OR EXON 21 L858R MUTATIONS - SUBSEQUENT THERAPY",
  "tree_id": "NSCL-23",
  "keywords": [
    "ROS1",
    "entrectinib",
    "crizotinib"
  ]
}
